Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    David Yeung 3Devendra HiwaseAgnes YONG w labcoat1

    Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong



    Session 2: TKI resistance / failure

    • When frontline therapy fails 
      (Dr David Yeung)
    • CML - beyond chronic phase
      (Dr Devendra Hiwase)
    • Allograft - still a role in CML?
      (Dr Agnes Yong)



    David Yeung 3



    When frontline therapy fails
    Dr David Yeung- SA Pathology, University of Adelaide

    • LASOR - failure to achieve 2009 ELN goals
    • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
    • ENESTcmr - failure to achieve deep molecular response
    • Ponatinib - drug of last resort?
    • Asciminib (ABL001) - rising star?


    Devendra Hiwase  

    CML - Beyond chronic phase?
    Dr Devendra Hiwase - SA Pathology, University of Adelaide

    • CML in accelerated phase (including patient case)
      • First-line IM in patients with newly diagnosed AP 
      • NIL following imatinib resistance or intolerance
      • DAS after imatinib failure
      • IM versus stem cell transplantation 
      • PON in patients with CML and PH+ ALL resistant/intolerant to IM
      • Treatment strategy recommendations for CML in AP
    • CML in blast crisis (including patient case)
      • Survival of CML blast crisis patients
      • Prognostic factors and survival outcomes in patients with CML in blast crisis
      • Further treatment options

    Agnes YONG w labcoat1


    Allograft - Still a role in CML?
    Dr Agnes Yong - SA Pathology, University of Adelaide

    • Historic overview of allogeneic stem cell transplantation in CML
    • Survival rates after transplantation
    • EBMT score for alloSCT in CML?
    • Which CML patient needs transplant?
    • Which conditioning regime for alloSCT?
    • Role of TKI's after transplant
    • Summary